WebApr 10, 2016 · Anthim (obiltoxaximab) is an injectable drug developed by Elusys Therapeutics for the treatment of inhalational anthrax caused by bacillus anthracis. Elusys Therapeutics submitted the biological license application (BLA) for the drug to the US Food and Drug Administration (FDA) on 20 March 2015. The BLA was accepted by … WebMar 21, 2016 · Since 2002, Elusys has received over $240 million in grants and contracts to support ANTHIM's development, from the Office of the Assistant Secretary for Preparedness and Response (ASPR) of the ...
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, …
WebHeat Biologics, Inc. recently announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM (obiltoxaximab) Injection, pursuant to which Elusys will merge into a wholly owned subsidiary of Heat. The acquisition is expected to close during the first ... WebApr 11, 2024 · To date, Elusys has won over $400 million in research and development contracts and procurement orders and was recently awarded a CAD$7.9 (USD $6.0) … au占い 天秤座
Heat Biologics (NightHawk Biosciences) Announces that its Elusys ...
WebApr 27, 2024 · New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by NightHawkDURHAM, N.C., April 27, 2024 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE ... WebDec 2, 2024 · Elusys was awarded two delivery orders from the U.S. government – $45 million in 2015 and $25 million in 2024 – to produce Anthim for the U.S. Strategic National Stockpile (SNS), the U.S ... WebANTHIM® (obiltoxaximab) is a monoclonal anthrax antitoxin licensed in the United States, Canada, United Kingdom, and the European Union. ANTHIM® has been delivered to the … au 占い 迷惑メール